Yasuhide Kitagawa1, Satoru Ueno2, Kouji Izumi2, Yoshifumi Kadono2, Atsushi Mizokami2, Shiro Hinotsu3, Hideyuki Akaza4, Mikio Namiki2. 1. Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Takaramachi 13-1, Kanazawa, Ishikawa, 920-8640, Japan. yasukita@med.kanazawa-u.ac.jp. 2. Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Takaramachi 13-1, Kanazawa, Ishikawa, 920-8640, Japan. 3. Center of Innovative Clinical Medicine, Okayama University, Okayama, Japan. 4. Department of Strategic Investigation on Comprehensive Cancer Network Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Abstract
PURPOSE: To investigate the clinical outcomes of metastatic prostate cancer patients and the relationship between nadir prostate-specific antigen (PSA) levels and different types of primary androgen deprivation therapy (PADT). This study utilized data from the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database. METHODS: A total of 2982 patients treated with PADT were enrolled. Kaplan-Meier analysis was used to compare progression-free survival (PFS) and overall survival (OS) in patients treated using combined androgen blockade (CAB) and non-CAB therapies. The relationships between nadir PSA levels and PADT type according to initial serum PSA levels were also investigated. RESULTS: Among the 2982 enrolled patients, 2101 (70.5 %) were treated with CAB. Although CAB-treated patients had worse clinical characteristics, their probability of PFS and OS was higher compared with those treated with a non-CAB therapy. These results were due to a survival benefit with CAB in patients with an initial PSA level of 500-1000 ng/mL. Nadir PSA levels were significantly lower in CAB patients than in non-CAB patients with comparable initial serum PSA levels. CONCLUSIONS: A small survival benefit for CAB in metastatic prostate cancer was demonstrated in a Japanese large-scale prospective cohort study. The clinical significance of nadir PSA levels following PADT was evident, but the predictive impact of PSA nadir on OS was different between CAB and non-CAB therapy.
PURPOSE: To investigate the clinical outcomes of metastatic prostate cancerpatients and the relationship between nadirprostate-specific antigen (PSA) levels and different types of primary androgen deprivation therapy (PADT). This study utilized data from the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database. METHODS: A total of 2982 patients treated with PADT were enrolled. Kaplan-Meier analysis was used to compare progression-free survival (PFS) and overall survival (OS) in patients treated using combined androgen blockade (CAB) and non-CAB therapies. The relationships between nadirPSA levels and PADT type according to initial serum PSA levels were also investigated. RESULTS: Among the 2982 enrolled patients, 2101 (70.5 %) were treated with CAB. Although CAB-treated patients had worse clinical characteristics, their probability of PFS and OS was higher compared with those treated with a non-CAB therapy. These results were due to a survival benefit with CAB in patients with an initial PSA level of 500-1000 ng/mL. NadirPSA levels were significantly lower in CABpatients than in non-CABpatients with comparable initial serum PSA levels. CONCLUSIONS: A small survival benefit for CAB in metastatic prostate cancer was demonstrated in a Japanese large-scale prospective cohort study. The clinical significance of nadirPSA levels following PADT was evident, but the predictive impact of PSAnadir on OS was different between CAB and non-CAB therapy.
Entities:
Keywords:
Combined androgen blockade; Nadir PSA level; Outcome predictor; Primary androgen deprivation; Prostate cancer
Authors: M Usami; H Akaza; Y Arai; Y Hirano; S Kagawa; H Kanetake; S Naito; Y Sumiyoshi; Y Takimoto; A Terai; H Yoshida; Y Ohashi Journal: Prostate Cancer Prostatic Dis Date: 2007-01-02 Impact factor: 5.554
Authors: Brandon Bernard; Vinayak Muralidhar; Yu-Hui Chen; Srikala S Sridhar; Edith P Mitchell; Curtis A Pettaway; Michael A Carducci; Paul L Nguyen; Christopher J Sweeney Journal: Cancer Date: 2017-01-05 Impact factor: 6.860